PA-23-317 is a grant from the National Institutes of Health (NIH) that funds competing revisions and administrative supplements to existing NIH single-project research grants and cooperative agreements. The program supports researchers who need to expand the scope or add new dimensions to active NIH-funded projects, with clinical trial components optional. Eligible applicants are current NIH grant recipients at participating institutes including NIAID, NIMH, NCI, NIDDK, NICHD, NIDA, NIEHS, and others. Applicants must have an active single-project research grant or cooperative agreement, and competing revision notices of special interest from individual institutes specify eligible activity codes.

NIH Research Program Projects (Parent P01 Clinical Trial Optional) is sponsored by National Institutes of Health. NIH Research Program Projects (Parent P01 Clinical Trial Optional) is a forecasted funding opportunity on Grants.gov from National Institutes of Health. Fiscal Year: 2027. Assistance Listing Number(s): 93.393. <p>The National Institutes of Health (NIH) pursues its mission of seeking fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. Through this Notice of Funding Opportunity (NOFO), the participating NIH Institutes, Centers, and Offices (ICOs) encourage pursuit of that mission through the submission of investigator-initiated Program Project (P01) applications. With this Parent ...

The Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) is a cooperative agreement grant from the National Institutes of Health (NIH), administered by the National Institute of Neurological Disorders and Stroke (NINDS). The program funds research to clinically validate candidate biomarkers for neurological or neuromuscular disorders, with clinical trials permitted but not required. Eligible applicants include U.S. research institutions, universities, and other organizations eligible to receive NIH funding. The deadline for this funding opportunity is June 22, 2026. This opportunity was updated in March 2025 to align with agency priorities, and applicants should carefully reread the full funding opportunity before submission. Applications must be submitted through NIH's standard electronic systems.

Forecast to Publish a Funding Opportunity Announcement for Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) is sponsored by National Institutes of Health. Forecast to Publish a Funding Opportunity Announcement for Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) is a forecasted funding opportunity on Grants.gov from National Institutes of Health. Fiscal Year: 2026. Assistance Listing Number(s): 93.395, 93.396, 93.393, 93.394, 93.399. <p>The National Cancer Institute intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health...

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required) is sponsored by National Institutes of Health. Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required) is a forecasted funding opportunity on Grants.gov from National Institutes of Health. Fiscal Year: 2027. Assistance Listing Number(s): 93.395. <p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). This is a re-issuance of <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-284.html">PAR-23-284</a>. The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and...